Table 1. Patient characteristics for the groups with Gleason score ≤7 or >7 and differences in HIF1α expression between the groups.

	HIF1α positive		HIF1α negative
	Gleason score ≤7	Gleason score >7	Gleason score ≤7	Gleason score >7
Number of patients	29	54	9	8
Mean age (years)	59.9	70.7	62.2	68.1
Tumor Stage (T1–T2)	23	9†	8	3†
Tumor Stage (T3–T4¥)	6	29†	1	4†
Median pre-interventional PSA*	6.4 (1.4 – 43)	14 (0.7 – 483.7)	5.4 (4 – 10.2)	14.8 (2 – 40.2)
Median follow-up from diagnosisin years	2.3	3.6	2.4	3.3
Patients started on androgendeprivation therapy¥	0	38	0	5

The group with Gleason score ≤7 was comprised of Gleason score <6 (6), 6 (28) and 7 (4) and the group with Gleason score >7 was comprised of scores 8 (8), 9 (52) and 10 (2).

^†There were 17 patients with missing data for tumor stage in the group with Gleason score >7 and 16 of these patients were HIF1α positive.

^¥There was no significant association with HIF1α expression and Gleason scores when analyzed using Pearson’s Chi-squared test or Fisher’s exact test using two-by-two tables.

^*Pre-interventional PSA was defined as PSA immediately prior to obtaining the tissue sample.